In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin
about
Retinol (Vitamin A) Increases α-Synuclein, β-Amyloid Peptide, Tau Phosphorylation and RAGE Content in Human SH-SY5Y Neuronal Cell Line.TracMouse: A computer aided movement analysis script for the mouse inverted horizontal grid testHMGB1 Mediates Autophagy Dysfunction via Perturbing Beclin1-Vps34 Complex in Dopaminergic Cell ModelNeuroprotective Effects of Echinacoside on Regulating the Stress-Active p38MAPK and NF-κB p52 Signals in the Mice Model of Parkinson's Disease.Regulation of striatal astrocytic receptor for advanced glycation end-products variants in an early stage of experimental Parkinson's disease.Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA-induced dopaminergic denervationAn adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.Astroglial DJ-1 over-expression up-regulates proteins involved in redox regulation and is neuroprotective in vivo.Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson’s Disease.TLR9 activation via microglial glucocorticoid receptors contributes to degeneration of midbrain dopamine neurons.Jia-Jian-Di-Huang-Yin-Zi decoction exerts neuroprotective effects on dopaminergic neurons and their microenvironment.Glycyrrhizin Protects Mice Against Experimental Autoimmune Encephalomyelitis by Inhibiting High-Mobility Group Box 1 (HMGB1) Expression and Neuronal HMGB1 Release.
P2860
Q36369915-E88CA7BC-B1BB-4CB7-8CAD-BF61F227361CQ37508349-5953CCE4-172F-421F-9909-9FC0F60CCD80Q37614664-D91DCACD-F80A-44CA-A8E6-44B2DE2BAD37Q38782208-5F0B14F9-6476-4FC9-99E7-C3566264C827Q38862845-E64B2F9D-F2AD-4F3B-B53A-014A6DE7B926Q39018573-FDC2FF08-03A7-4ADC-8D39-ECFD9D0BF9D3Q48171351-8A02F4E1-3C7B-4E4E-81A5-C50D944A634EQ53437162-94DB5456-6A14-4C92-A942-711FEE07D118Q55226753-B741A015-61D0-4BAB-A751-B2AF24D0D689Q55399332-D00E81C4-7F74-47D5-A251-103188A007D8Q55516053-F9C3DCCB-5CEA-4AA2-A1F0-8367655C3473Q55714316-FD6FB568-0528-48A0-860A-D04C28F9AFC6
P2860
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
In-vivo evidence that high mob ...... be attenuated by glycyrrhizin
@en
In-vivo evidence that high mob ...... be attenuated by glycyrrhizin
@nl
type
label
In-vivo evidence that high mob ...... be attenuated by glycyrrhizin
@en
In-vivo evidence that high mob ...... be attenuated by glycyrrhizin
@nl
prefLabel
In-vivo evidence that high mob ...... be attenuated by glycyrrhizin
@en
In-vivo evidence that high mob ...... be attenuated by glycyrrhizin
@nl
P2093
P2860
P50
P1476
In-vivo evidence that high mob ...... be attenuated by glycyrrhizin
@en
P2093
Gernot Riedel
Heather L Martin
John V Forrester
Markus A Hobert
Matteo Santoro
Peter Teismann
Petros Stathakos
Tim W Rattay
P2860
P356
10.1016/J.NBD.2016.02.018
P577
2016-02-24T00:00:00Z